Riccardo Mazza։ Personalized Anticoagulation in Atrial Fibrillation
Riccardo Mazza, Cardiology Resident at University Vita-Salute San Raffaele, shared a post on LinkedIn about a recent article he co-authored with Cosmo Godino, adding:
՛՛Our response to the Letter to the Editor by Magdelijns et al. has been published in the Journal of Thrombosis and Haemostasis.
The concept of ‘one-size-fits-all’ anticoagulation may have limitations in contemporary AF management.
Personalized anticoagulation is progressively moving from theoretical consideration to clinical discussion.
We are grateful for the ongoing scientific discussion and look forward to the results of the DOAC-FRAIL trial.՛՛
Title: Plasma levels measurement of the 4 direct oral anticoagulants in patients with atrial fibrillation at the time of acute thromboembolic and bleeding events: reply
Authors: Cosmo Godino, Riccardo Mazza
Read the Full Article on Journal of Thrombosis and Haemostasis․
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 7, 2026, 07:57Edward Lee Carter: When Should Apixaban Become the Default for Acute VTE?
-
Oct 7, 2026, 07:40Annette Bowyer: Exploring New Developments in Thrombin Generation
-
Oct 7, 2026, 07:06Omid Seidizadeh: When Acquired von Willebrand Syndrome Takes Different Paths
-
Oct 7, 2026, 06:49Neeraj Songara: Can a Negative Antibody Screen Be Misleading?
-
Oct 7, 2026, 04:09James P. Crowley: Could the Microbiome Protect Us From Severe EBV Infection?
-
Oct 7, 2026, 03:58Sohanur Rohanman Sohan: Explainable AI for Anemia Prediction Using Machine Learning
-
Oct 7, 2026, 03:00Sandeep Kumar: A Second Chance for a Child with Fanconi Anemia
-
Oct 7, 2026, 02:41Kemal Karaagac: Optimising DOAC Resumption After Major Bleeding in Atrial Fibrillation
-
Oct 7, 2026, 02:21Joseph Aslan: mPTP Inhibition Targets Platelet Procoagulant Activity and Thrombosis